Further suppressing anti-tumor immune responses, VIRMA also controls the m6A modification levels of chemokines and inflammatory cytokines (like CXCL1 and IL-6), which encourages the growth of myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) in the tumor microenvironment (39). This evidence concerns the gene CXCL1 and neoplasm.